Ruxolitinib for Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome: Two Pediatric Cases and Literature Review - Takeaways - MDSpire

Ruxolitinib for Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome: Two Pediatric Cases and Literature Review

  • By

  • Liu, Honglin

  • Zhang, Wei

  • May 5, 2026

  • 0 min

Share

  • 1

    Ruxolitinib was evaluated for efficacy and safety in children with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.

  • 2

    Two pediatric patients with refractory sJIA-MAS showed marked improvement in systemic hyperinflammation after ruxolitinib treatment.

  • 3

    In both cases, glucocorticoids were successfully tapered and discontinued without relapse following ruxolitinib therapy.

  • 4

    A review of seven pediatric cases indicated that five achieved complete remission with ruxolitinib, while two had partial remission.

  • 5

    No deaths occurred, but one patient developed Epstein–Barr virus-related complications after ruxolitinib, which resolved after treatment cessation.

Original Source(s)

Ruxolitinib for Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome: Two Pediatric Cases and Literature Review

  • by Liu, Honglin , Zhang, Wei

  • May 5, 2026

Related Content

Semaglutide Use Linked to Erythromelalgia Remission

Case details diagnostic workup and rapid symptom resolution following GLP-1 receptor agonist initiation.

Case Report Shows Carbimazole's ‘Triple-Hit’

Diffuse alveolar hemorrhage with coexistent antiphospholipid syndrome complicated anticoagulation therapy and created competing bleeding and thrombosis risks.

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness